SAN DIEGO, Calif. & MARCY L'ETOILE, France--(BUSINESS WIRE)--Regulatory News:
Quidel Corporation (NASDAQ: QDEL) and bioMérieux (Paris:BIM) have agreed to form a long-term global alliance in the area of rapid clinical diagnostics for the point-of-care. bioMérieux will become Quidel’s primary distributor for its QuickVue® rapid diagnostic tests outside the United States and the two companies intend to co-develop new rapid tests using Quidel’s market leading rapid test development capability and bioMérieux’s expertise and extensive library of antibodies and antigens. The companies will especially leverage their mutual expertise in the area of infectious diseases.
